$1.04
-0.01[-0.95%]
At close: May 17
$1.04
0[0.00%]
After Hours: 7:46PM EDT
bluebird bio
(NASDAQ:BLUE)bluebird bio Stock (NASDAQ:BLUE), Analyst Ratings, Price Targets, Predictions
bluebird bio Inc has a consensus price target of $8.37, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Wells Fargo, and Wedbush on March 27, 2024, March 27, 2024, and March 19, 2024. With an average price target of $3.56 between RBC Capital, Wells Fargo, and Wedbush, there's an implied 242.31% upside for bluebird bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Wells Fargo
Wedbush
HSBC
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for bluebird bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/27/2024 | Buy Now | 476.92% | RBC Capital | Luca Issi | → $8 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/27/2024 | Buy Now | 188.46% | Wells Fargo | Yanan Zhu | $4 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/19/2024 | Buy Now | 61.54% | Wedbush | David Nierengarten | $3 → $1.68 | Maintains | Neutral | Get Alert |
| 03/05/2024 | Buy Now | -1.92% | HSBC | Morten Herholdt | $2.31 → $1.02 | Maintains | Reduce | Get Alert |
| 12/21/2023 | Buy Now | 380.77% | B of A Securities | Jason Gerberry | $12 → $5 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 380.77% | Wells Fargo | Yanan Zhu | $8 → $5 | Maintains | Equal-Weight | Get Alert |
| 12/12/2023 | Buy Now | 573.08% | Baird | Jack Allen | $10 → $7 | Maintains | Outperform | Get Alert |
| 12/11/2023 | Buy Now | 1053.85% | B of A Securities | Jason Gerberry | $11 → $12 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 573.08% | Morgan Stanley | Jeffrey Hung | $3 → $7 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | 1150% | Raymond James | Dane Leone | $10 → $13 | Maintains | Outperform | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Initiates | → Neutral | Get Alert |
| 09/06/2023 | Buy Now | 304.81% | HSBC | Morten Herholdt | → $4.21 | Initiates | → Buy | Get Alert |
| 07/19/2023 | Buy Now | 861.54% | B of A Securities | Jason Gerberry | $6 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 07/11/2023 | Buy Now | 188.46% | Morgan Stanley | Matthew Harrison | $3 → $3 | Reiterates | Underweight → Underweight | Get Alert |
| 06/01/2023 | Buy Now | 669.23% | Barclays | Gena Wang | $7 → $8 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/28/2023 | Buy Now | 573.08% | JP Morgan | Eric Joseph | → $7 | Initiates | → Overweight | Get Alert |
| 04/03/2023 | Buy Now | 188.46% | Morgan Stanley | Matthew Harrison | $4 → $3 | Maintains | Underweight | Get Alert |
| 03/30/2023 | Buy Now | 669.23% | RBC Capital | Luca Issi | → $8 | Reiterates | → Sector Perform | Get Alert |
| 03/30/2023 | Buy Now | 476.92% | B of A Securities | Jason Gerberry | $8 → $6 | Maintains | Neutral | Get Alert |
| 03/07/2023 | Buy Now | 861.54% | Baird | Jack Allen | → $10 | Initiates | → Outperform | Get Alert |
| 01/24/2023 | Buy Now | 284.62% | Morgan Stanley | Matthew Harrison | $3 → $4 | Maintains | Underweight | Get Alert |
| 01/23/2023 | Buy Now | 669.23% | SVB Leerink | Mani Foroohar | $9 → $8 | Maintains | Market Perform | Get Alert |
| 01/06/2023 | Buy Now | 765.38% | SVB Leerink | Mani Foroohar | $8 → $9 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 669.23% | RBC Capital | Luca Issi | $100 → $8 | Maintains | Sector Perform | Get Alert |
| 09/20/2022 | Buy Now | 861.54% | Raymond James | Dane Leone | $8 → $10 | Maintains | Outperform | Get Alert |
| 08/19/2022 | Buy Now | 188.46% | Goldman Sachs | Salveen Richter | $2 → $3 | Maintains | Sell | Get Alert |
| 08/18/2022 | Buy Now | 861.54% | SVB Leerink | Mani Foroohar | $8 → $10 | Maintains | Market Perform | Get Alert |
| 08/05/2022 | Buy Now | 380.77% | Barclays | Gena Wang | $3 → $5 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/02/2022 | Buy Now | 669.23% | Raymond James | Dane Leone | → $8 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/24/2022 | Buy Now | 92.31% | Goldman Sachs | Salveen Richter | $3 → $2 | Maintains | Sell | Get Alert |
FAQ
What is the target price for bluebird bio (BLUE)?
The latest price target for bluebird bio (NASDAQ: BLUE) was reported by RBC Capital on March 27, 2024. The analyst firm set a price target for $6.00 expecting BLUE to rise to within 12 months (a possible 476.92% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for bluebird bio (BLUE)?
The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by RBC Capital, and bluebird bio reiterated their sector perform rating.
When was the last upgrade for bluebird bio (BLUE)?
The last upgrade for bluebird bio Inc happened on December 8, 2023 when Morgan Stanley raised their price target to $7. Morgan Stanley previously had an underweight for bluebird bio Inc.
When was the last downgrade for bluebird bio (BLUE)?
The last downgrade for bluebird bio Inc happened on April 6, 2022 when Cowen & Co. changed their price target from N/A to N/A for bluebird bio Inc.
When is the next analyst rating going to be posted or updated for bluebird bio (BLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
Is the Analyst Rating bluebird bio (BLUE) correct?
While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a reiterated with a price target of $0.00 to $6.00. The current price bluebird bio (BLUE) is trading at is $1.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.